Estrogen receptor β2 is inversely correlated with Ki-67 in hyperplastic and noninvasive neoplastic breast lesions

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 6, 2014, Pages 1057-1066

  Chantzi, Niki I ^a,b   Palaiologou, Marina ^a   Stylianidou, Artemis ^c   Goutas, Nikos ^d   Vassilaros, Stamatis ^e   Kourea, Helen P ^f   Dhimolea, Eugen ^b   Mitsiou, Dimitra J ^b   Tiniakos, Dina G ^a,g   Alexis, Michael N ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b INSTITUTE OF BIOLOGY   (Greece)

^c General District Hospital Helena Venizelou   (Greece)

^d Evgenidio Infirmary   (Greece)

^e Prolipsis Diagnostic Center   (Greece)

^f UNIVERSITY OF PATRAS   (Greece)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Breast; Ductal carcinoma in situ; ER 1; ER 2; Hyperplasia; i 67

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA1; ESTROGEN RECEPTOR BETA2; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; APOCRINE METAPLASIA; ARTICLE; ATYPICAL HYPERPLASIA; BREAST CARCINOGENESIS; BREAST DISEASE; BREAST HYPERPLASIA; BREAST LESION; CANCER GRADING; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL HYPERPLASIA OF USUAL TYPE; FEMALE; HEALTH STATUS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LABELING INDEX; MAJOR CLINICAL STUDY; MENOPAUSE; METAPLASIA; NONINVASIVE NEOPLASTIC BREAST LESION; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; APOCRINE GLANDS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CASE-CONTROL STUDIES; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; METAPLASIA; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901338598     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1652-0     Document Type: Article

References (48)

1. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P (2004) Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11:537-551. doi:10.1677/erc.1.00800 (Pubitemid 39331282)
2. Bartella V, Rizza P, Barone I, Zito D, Giordano F, Giordano C, Catalano S, Mauro L, Sisci D, Panno ML, Fuqua SA, Andò S (2012) Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter. Breast Cancer Res Treat 134:569-581. doi:10.1007/s10549-012- 2090-9
3. Bozkurt KK, Kapucuoǧlu N (2012) Investigation of immunohistochemical ERα, ERβ and ERßcx expressions in normal and neoplastic breast tissues. Pathol Res Pract 208:133-139. doi:10.1016/j.prp.2011.12.015
4. Chang EC, Frasor J, Komm B, Katzenellenbogen BS (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147:4831-4842. doi:10.1210/en.2006-0563 (Pubitemid 44402189)
5. Chantzi NI, Meligova AK, Dhimolea E, Petrou CC, Mitsiou DJ, Magafa V, Pechtelidou A, Florentin I, Kitraki E, Cordopatis P, Tiniakos DG, Alexis MN (2011) Insights into ectopic estrogen receptor expression, nucleocytoplasmic distribution and interaction with chromatin obtained with new antibodies to estrogen receptors α and β. Steroids 76:974-985. doi:10.1016/j. steroids.2011.05.010
6. Chantzi NI, Tiniakos DG, Palaiologou M, Goutas N, Filippidis T, Vassilaros SD, Dhimolea E, Mitsiou DJ, Alexis MN (2013) Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma. J Cancer Res Clin Oncol 139:1489-1498. doi:10.1007/s00432-013-1467-4
7. Claus EB, Chu P, Howe CL, Davison TL, Stern DF, Carter D, DiGiovanna MP (2001) Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol 70:303-316. doi:10.1006/exmp.2001.2366 (Pubitemid 32607203)
8. Dowsett M, A'Hern R, Salter J, Zabaglo L, Smith IE (2009) Who would have thought a single Ki67 measurement would predict long-term outcome? Breast Cancer Res 11(Suppl 3):S15. doi:10.1186/bcr2434
9. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, Warner M, Gustafsson JA, Rochefort H (2005) Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res 11:3170-3174. doi:10.1006/exmp.2001.2366 (Pubitemid 40637201)
10. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674. doi:10.1016/j.cell.2011.02.013
11. Henderson BE, Feigelson HS (2000) Hormonal carcinogenesis. Carcinogenesis 21:427-433. doi:10.1093/carcin/21.3.427 (Pubitemid 30137927)
12. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G (2008) Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26:3727-3734. doi:10.1200/JCO.2007.14.2968
13. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ (1998) Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90:37-42. doi:10.1093/jnci/90.1.37 (Pubitemid 28078079)
14. Leung YK, Mak P, Hassan S, Ho SM (2006) Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA 103:13162-13167. doi:10.1073/pnas.0605676103 (Pubitemid 44338933)
15. Leung YK, Lee MT, Lam HM, Tarapore P, Ho SM (2012) Estrogen receptor-beta and breast cancer: translating biology into clinical practice. Steroids 77:727-737. doi:10.1016/j.steroids.2012.03.008
16. Leygue E, Murphy LC (2013) A bi-faceted role of estrogen receptor β in breast cancer. Endocr Relat Cancer 20:R127-R139. doi:10.1530/ERC-12-0389
17. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchió C, Reis-Filho JS (2010) Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 57:171-192. doi:10.1111/j.1365-2559.2010.03568.x
18. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM (1998) Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247:75-78 (Pubitemid 28412528)
19. Morelli C, Lanzino M, Garofalo C, Maris P, Brunelli E, Casaburi I, Catalano S, Bruno R, Sisci D, Andò S (2010) Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells. Mol Cell Biol 30:857-8570. doi:10.1128/MCB.00824-09
20. Murphy LC, Leygue E (2012) The role of estrogen receptor-β in breast cancer. Semin Reprod Med 30:5-13. doi:10.1055/s-0031-1299592
21. Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, Keramopoulos A (2004) The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 57:523-528. doi:10.1136/jcp.2003.008599 (Pubitemid 38655949)
22. Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M (2008) A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 10:R74. doi:10.1186/bcr2139
23. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26:3505-3512. doi:10.1093/nar/26.15.3505 (Pubitemid 28347221)
24. Palmieri C, Lam EW, Mansi J, MacDonald C, Shousha S, Madden P, Omoto Y, Sunters A, Warner M, Gustafsson JA, Coombes RC (2004) The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 10:2421-2428. doi:10.1158/1078-0432.CCR-03-0215 (Pubitemid 38445702)
25. Park BW, Kim KS, Heo MK, Yang WI, Kim SI, Kim JH, Kim GE, Lee KS (2006) The changes of estrogen receptor-beta variants expression in breast carcinogenesis: decrease of estrogen receptor-beta2 expression is the key event in breast cancer development. J Surg Oncol 93:504-510. doi:10.1002/jso.20336 (Pubitemid 44651275)
26. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64:423-428. doi:10.1158/0008-5472.CAN-03-2446 (Pubitemid 38114127)
27. Patani N, Martin LA, Dowsett M (2013) Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer 33:1-13. doi:10.1002/ijc.27997
28. Peng B, Lu B, Leygue E, Murphy LC (2003) Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol 30:13-29. doi:10.1677/jme.0.0300013 (Pubitemid 36305253)
29. Powell E, Shanle E, Brinkman A, Li J, Keles S, Wisinski KB, Huang W, Xu W (2012) Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that coexpress ERα and ERβ. PLoS ONE 7:e30993. doi:10.1371/journal.pone.0030993
30. Rhodes A, Jasani B, Balaton AJ, Miller KD (2000) Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 53:292-301. doi:10.1136/jcp.53.4.292 (Pubitemid 30180402)
31. Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, Kissler S, Gätje R, Karn T, Kaufmann M (2005) Methylation of estrogen receptor beta promoter correlates with loss of ERbeta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer 12:903-916. doi:10.1677/erc.1.01088 (Pubitemid 41815784)
32. Roger P, Sahla ME, Mäkelä S, Gustafsson JA, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537-2541 (Pubitemid 32685835)
33. Román-Pérez E, Casbas-Hernández P, Pirone JR, Rein J, Carey LA, Lubet RA, Mani SA, Amos KD, Troester MA (2012) Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res 14:R51. doi:10.1186/bcr3152
34. Selim AG, Wells CA (1999) Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors. J Clin Pathol 52:838-841. doi:10.1136/jcp.52.11.838
35. Shaaban AM, Sloane JP, West CR, Foster CS (2002) Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol 60:597-604 (Pubitemid 34160337)
36. Shaaban AM, O'Neill PA, Davies MP, Sibson R, West CR, Smith PH, Foster CS (2003) Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 27:1502-1512 (Pubitemid 37486611)
37. Shaaban AM, Jarvis C, Moore F, West C, Dodson A, Foster CS (2005) Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol 29:1593-1599
38. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V (2008) Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14:5228-5235. doi:10.1158/1078-0432.CCR-07-4528
39. Sharma P, Kimler BF, Warner C, Metheny T, Xue Q, Zalles CM, Fabian CJ (2006) Estrogen receptor expression in benign breast ductal cells obtained from random periareolar fine needle aspiration correlates with menopausal status and cytomorphology index score. Breast Cancer Res Treat 100:71-76. doi:10.1007/s10549-006-9234-8
40. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP (1999) Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 188:237-244. doi:10.1002/(SICI)10969896(199907)188:3 〈237:AIDPAT H343〉3.0.CO;2-8
41. Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC (2006) Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 95:616-626. doi:10.1038/sj.bjc.6603295 (Pubitemid 44325902)
42. Skliris GP, Leygue E, Watson PH, Murphy LC (2008) Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol 109:1-10. doi:10.1016/j.jsbmb.2007.12.010
43. Snyder MA, Smejkalova T, Forlano PM, Woolley CS (2010) Multiple ERbeta antisera label in ERbeta knockout and null mouse tissues. J Neurosci Methods 188:226-234. doi:10.1016/j.jneumeth.2010.02.012
44. Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA (2004) Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101:1566-1571. doi:10.1073/pnas.0308319100 (Pubitemid 38236167)
45. Thomas C, Gustafsson JÅ (2011) The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11:597-608. doi:10.1038/nrc3093
46. van Diest PJ, van der Wall E, Baak JP (2004) Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 57:675-681. doi:10.1136/jcp.2003.010777
47. Zhao C, Matthews J, Tujague M, Wan J, Ström A, Toresson G, Lam EW, Cheng G, Gustafsson JA, Dahlman-Wright K (2007) Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res 67:3955-3962. doi:10.1158/0008-5472.CAN-06-3505 (Pubitemid 46762185)
48. Zou Y, Tsai WB, Cheng CJ, Hsu C, Chung YM, Li PC, Lin SH, Hu MC (2008) Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Res 10:R21. doi:10.1186/bcr1872